Connection

Inderjit Singh to Encephalomyelitis, Autoimmune, Experimental

Back to Details
This is a "connection" page, showing publications Inderjit Singh has written about Encephalomyelitis, Autoimmune, Experimental.
Inderjit Singh
Connection Strength
6.856
Encephalomyelitis, Autoimmune, Experimental
  1. Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis. Immunology. 2021 11; 164(3):602-616.
    View in: PubMed
    Score: 0.687
  2. Regulation of B cell functions by S-nitrosoglutathione in the EAE model. Redox Biol. 2021 09; 45:102053.
    View in: PubMed
    Score: 0.682
  3. Detoxification of Reactive Aldehydes by Alda-1 Treatment Ameliorates Experimental Autoimmune Encephalomyelitis in Mice. Neuroscience. 2021 03 15; 458:31-42.
    View in: PubMed
    Score: 0.662
  4. Regulation of IL-10 and IL-17 mediated experimental autoimmune encephalomyelitis by S-nitrosoglutathione. Immunobiology. 2018 10; 223(10):549-554.
    View in: PubMed
    Score: 0.554
  5. S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis. Free Radic Biol Med. 2018 06; 121:57-68.
    View in: PubMed
    Score: 0.547
  6. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis. PLoS One. 2015; 10(10):e0141781.
    View in: PubMed
    Score: 0.461
  7. AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model. Am J Pathol. 2013 Aug; 183(2):526-41.
    View in: PubMed
    Score: 0.391
  8. Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis. Am J Pathol. 2012 Sep; 181(3):993-1006.
    View in: PubMed
    Score: 0.367
  9. S-nitrosoglutathione a physiologic nitric oxide carrier attenuates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010 Jun; 5(2):240-51.
    View in: PubMed
    Score: 0.309
  10. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol. 2008 May; 73(5):1381-93.
    View in: PubMed
    Score: 0.269
  11. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology. 2006 Jul; 118(3):384-91.
    View in: PubMed
    Score: 0.241
  12. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 2005 Sep; 19(11):1407-21.
    View in: PubMed
    Score: 0.228
  13. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol. 2005 Jul 01; 175(1):566-74.
    View in: PubMed
    Score: 0.225
  14. Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res. 2004 Oct 01; 1022(1-2):1-11.
    View in: PubMed
    Score: 0.214
  15. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res. 2004 Jul 01; 77(1):63-81.
    View in: PubMed
    Score: 0.210
  16. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999 Jul 09; 269(2):71-4.
    View in: PubMed
    Score: 0.149
  17. Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018 07; 154(3):434-451.
    View in: PubMed
    Score: 0.135
  18. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol. 2009 Jun 15; 182(12):8005-14.
    View in: PubMed
    Score: 0.074
  19. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun. 2009 Aug 14; 386(1):16-20.
    View in: PubMed
    Score: 0.074
  20. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia. 2009 Jan 15; 57(2):182-93.
    View in: PubMed
    Score: 0.072
  21. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol. 2008 Dec; 214(2):168-80.
    View in: PubMed
    Score: 0.070
  22. GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia. 2007 Jan 01; 55(1):65-77.
    View in: PubMed
    Score: 0.062
  23. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol. 2006 Sep; 169(3):1012-25.
    View in: PubMed
    Score: 0.061
  24. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res. 2006 Aug 15; 84(3):614-25.
    View in: PubMed
    Score: 0.061
  25. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol. 2004 Jan 15; 172(2):1273-86.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.